The most recent trading session ended with Adaptimmune Therapeutics PLC standing at $1.20, reflecting a -1.24% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 1.37%. At the same time, the Dow lost 1.35%, and the tech-heavy Nasdaq lost 1.8%.
Shares of the company have appreciated by 47.04% over the course of the past month, outperforming the Medical sector's gain of 2.25% and the S&P 500's gain of 5.1%.
Analysts and investors alike will be keeping a close eye on the performance of Adaptimmune Therapeutics PLC in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.12, indicating a 33.33% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $4.8 million, indicating a 56.48% decline compared to the corresponding quarter of the prior year.
Investors should also note any recent changes to analyst estimates for Adaptimmune Therapeutics PLC. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. As of now, Adaptimmune Therapeutics PLC holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 91, finds itself in the top 37% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Image: Bigstock
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
The most recent trading session ended with Adaptimmune Therapeutics PLC standing at $1.20, reflecting a -1.24% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 1.37%. At the same time, the Dow lost 1.35%, and the tech-heavy Nasdaq lost 1.8%.
Shares of the company have appreciated by 47.04% over the course of the past month, outperforming the Medical sector's gain of 2.25% and the S&P 500's gain of 5.1%.
Analysts and investors alike will be keeping a close eye on the performance of Adaptimmune Therapeutics PLC in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.12, indicating a 33.33% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $4.8 million, indicating a 56.48% decline compared to the corresponding quarter of the prior year.
Investors should also note any recent changes to analyst estimates for Adaptimmune Therapeutics PLC. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. As of now, Adaptimmune Therapeutics PLC holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 91, finds itself in the top 37% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.